101
|
Park IH, Lee KS, Im SA, Jung KH, Park KH, Im YH, Lee S, Kim YJ, Kim HJ, Lee S, Lee MH, Kim TY, Lee KH, Kim SB, Ahn JH, Nam BH, Ro J. Abstract OT3-1-08: The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot3-1-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Most patients with metastatic breast cancer (MBC) experience disease progression after being treated with an anthracycline or taxane. Irinotecan, a semisynthetic agent derived from the natural alkaloid camptothecin is metabolized to the active metabolite SN-38 which targets topoisomerase I leading to single and double strand DNA breaks. Irinotecan as a single agent demonstrated tumor activity with an objective response rate ranging from 5 to 23% in patients with MBC refractory to taxane and anthracycline. Irinotecan increased the activity of 5-FU, the active metabolite of capecitabine, and overcomes the negative effect of thymidylate synthase overexpression, which is the main target of an active metabolite of 5-FU. A phase II study that evaluated the efficacy and safety of irinotecan and capecitabin combination (IX) showed that the median progression free survival (PFS) was 7.6 months (95% CI, 5.0-10.2months), and the median OS was 22.6 months (95% CI, 15.4 – 29.8 months) with good tolerability in anthracycline and taxane pretreated MBC patients. Based on these results, we planned to conduct a multicenter, randomized phase III study which assesses the efficacy of irinotecan and capecitabine combination therapy compared with capecitabine alone in patients with anthracycline and taxane resistant MBC.
Methods: In this trial, patients with HER2 normal tumor who previously received anthracycline and taxane based chemotherapies are enrolled. Eligible patients are randomly assigned in a 1:1 ratio to receive irinotecan plus capecitabine or capecitabine alone. The primary end point of this trial is PFS and a total number of accrual patients will be 222. Randomization is done using a random block size permutation method and stratified by hormone receptor status (negative vs. positive), first line vs. ≥second lines, visceral metastasis (negative vs. positive). Patients receive irinotecan at 80 mg/m2 on day 1 and 8 every 3 weeks and capecitabine 1000mg/m2 bid from day 1 to day 14 every 3 weeks. In control arm, patients receive capecitabine 1250mg/m2 bid from day 1 to day 14 every 3 weeks. Response will be assessed using RECIST1.1 criteria and toxicity will be graded according to NCI-CTCAE 4.0 criteria. Study Status: A total of 107 patients consented for the study since June 2011, and accrual is ongoing. Clinical trial information: NCT01501669.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT3-1-08.
Collapse
|
102
|
Jung SY, Song EJ, You JY, Lee MH, Kwon Y, Ko KL, Park IH, Lee KS, Ro J, Lee S, Kang HS, Lee E, Shin KH. Abstract P3-08-14: Could the preoperative systemic therapy be a risk factor for breast cancer-related lymphedema in stage II/III breast cancer? Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-08-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The breast cancer-related lymphedema (LE) has been known to be closely related to axillary lymph nodes dissection (ALND), chemotherapy, and radiation therapy. In this study, we evaluated whether the sequence of systemic chemotherapy and surgery could be a predictive factor in stage II/III breast cancer.
Methods and Materials: A total of 867 patients with stage II/III breast cancer, who underwent curative surgery with adequate systemic therapy from 2004 to 2009, were retrospectively analyzed. Adjuvant chemotherapy (ACT) was performed in 571 patients (65.9%) and preoperative systemic chemotherapy (PSC) in 296 (34.1%). We evaluated the incidence of LE by clinicopathologic factors and treatments.
Results: At a median follow-up of 5.1 years (range, 3.0-8.3 years), 360 patients (41.5%) had experienced LE, 244 patients have retained LE (permanent LE), and 116 patents were normalized. The overall 5-year cumulative incidence of LE was 17%. LE occurred in 188 patients (32.9%) in patients with ACT, 172 patients (58.1%) with PSC (P<0.001), permanent LE in 121 (21.2%) with ACT, 123 (41.6%) with PSC (P<0.001), respectively. Multivariate analysis showed that PSC (hazard ratio [HR], 1.65; P<.001), radiotherapy (HR, 2.24; P<0.01), ALND (HR, 1.41; P = 0.04), and nodal stage (HR, 1.93; P = 0.04) were independent risk factors for LE occurrence. For the permanent LE, PSC (HR, 1.44; P = 0.05), radiotherapy (HR, 2.79; P<0.01), ALND (HR, 1.77; P<0.01), and nodal stage (HR, 3.01; P = 0.02) showed the associations.
Conclusions: The risk factors associated with LE were advanced stage, ALND and radiotherapy. PSC was one of predictors for transients LE. However, further evaluation should be done whether it is a risk factor for permanent LE.
This research was supported by National Cancer Center Grant NCC-1210181-2 by the National Cancer Center, Republic of Korea.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-08-14.
Collapse
|
103
|
Park IH, Kong SY, Ro JY, Kwon Y, Kang JH, Mo HJ, Jung SY, Lee S, Lee KS, Kang HS, Lee E, Ro J. Abstract P5-01-12: Prognostic implications of tumor-infiltrating lymphocytes (TIL) in association with PD-L1 expression, and serum cytokine levels in early breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-01-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Immune system has been known to influence the prognosis of breast cancer (BC). However, the relationship between immune modulating factor (PD-L1) and tumor infiltrating lymphocyte (TIL) profiles in breast cancer has yet to be revealed according to breast cancer subtypes. In addition, the effects of circulating cytokines on TILs have not been addressed.
Patients and methods
We investigated the relationship between the profiles of TILs and PD-L1 expression of the primary tumor tissue by immunohistochemistry with clinical outcomes in 253 patients who underwent surgery for early breast cancer at National Cancer Center from January 2001 to December 2005. Besides, the serum cytokines including IL-10, IL-18, IL-6, IFN-g, and TGF-β1 were measured at diagnosis. Clinical data including hormone receptors status, HER2 expression, disease free survival (DFS), and overall survival (OS) were collected.
Results
Median age of patients was 49 years (range, 32-74) and median follow-up was 8.5 years. One hundred eighty five (73.1%) patients had hormone receptor (HR) positive and 101 (39.9%) patients had node positive BC. CD8+ TILs were more abundant in low PD-L1 expressed tumor (P = 0.027), though there was no association between FOXP3+ TILs and PD-L1 expression (P = 0.585). A total number of TILs was higher in HR negative compared with HR positive BC (P = 0.061) and the expression of PD-L1 was more frequent in HR positive BC (P<0.001). In HR negative BC, there was a trend of longer DFS in patients with higher CD8+ TILs and low PD-L1 expression (P = 0.097). However, such association was not detected in HR positive BC patients. Among serum cytokines we examined, the higher levels of IL-18 were significantly associated with shorter DFS in HR negative BC (P = 0.006). In HR negative BC, higher CD8+ TILs with low PD-L1 expression and lower IL-18 were significantly related with better clinical outcomes when adjusted with other clinical factors (DFS, P = 0.032; OS, P = 0.048).
Conclusions
Lower PD-L1 expression in breast tumor was associated with higher CD8+ lymphocyte infiltration. Especially in HR negative BC, increasing CD8+ TILs with lower PD-L1 expression and lower serum IL-18 level were good prognostic factors. Further validation will be needed to establish the role of immune profiles in BC patients.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-01-12.
Collapse
|
104
|
Adare A, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Angerami A, Aoki K, Apadula N, Aramaki Y, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Bhom JH, Blau DS, Bok JS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Campbell S, Caringi A, Chen CH, Chi CY, Chiu M, Choi IJ, Choi JB, Choudhury RK, Christiansen P, Chujo T, Chung P, Chvala O, Cianciolo V, Citron Z, Cole BA, Conesa Del Valle Z, Connors M, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Dayananda MK, Denisov A, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Dutta D, D'Orazio L, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grim G, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ikeda Y, Imai K, Inaba M, Isenhower D, Ishihara M, Issah M, Ivanischev D, Iwanaga Y, Jacak BV, Jia J, Jiang X, Jin J, Johnson BM, Jones T, Joo KS, Jouan D, Jumper DS, Kajihara F, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim A, Kim BI, Kim DJ, Kim EJ, Kim YJ, Kinney E, Kiss Á, Kistenev E, Kleinjan D, Kochenda L, Komkov B, Konno M, Koster J, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee KB, Lee KS, Leitch MJ, Leite MAL, Li X, Lichtenwalner P, Liebing P, Linden Levy LA, Liška T, Liu H, Liu MX, Love B, Lynch D, Maguire CF, Makdisi YI, Malik MD, Manko VI, Mannel E, Mao Y, Masui H, Matathias F, McCumber M, McGaughey PL, McGlinchey D, Means N, Meredith B, Miake Y, Mibe T, Mignerey AC, Miki K, Milov A, Mitchell JT, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Murakami T, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nam S, Newby J, Nguyen M, Nihashi M, Nouicer R, Nyanin AS, Oakley C, O'Brien E, Oda SX, Ogilvie CA, Oka M, Okada K, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park IH, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Perepelitsa D, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Qu H, Rak J, Ravinovich I, Read KF, Rembeczki S, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Ružička P, Sahlmueller B, Saito N, Sakaguchi T, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Themann H, Thomas D, Thomas TL, Togawa M, Toia A, Tomášek L, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Woody CL, Wright RM, Wysocki M, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zhou S. Quadrupole anisotropy in dihadron azimuthal correlations in central d+Au collisions at √(s(NN))=200 GeV. PHYSICAL REVIEW LETTERS 2013; 111:212301. [PMID: 24313481 DOI: 10.1103/physrevlett.111.212301] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/11/2013] [Revised: 06/18/2013] [Indexed: 06/02/2023]
Abstract
The PHENIX collaboration at the Relativistic Heavy Ion Collider (RHIC) reports measurements of azimuthal dihadron correlations near midrapidity in d+Au collisions at √(s(NN))=200 GeV. These measurements complement recent analyses by experiments at the Large Hadron Collider (LHC) involving central p+Pb collisions at √(s(NN))=5.02 TeV, which have indicated strong anisotropic long-range correlations in angular distributions of hadron pairs. The origin of these anisotropies is currently unknown. Various competing explanations include parton saturation and hydrodynamic flow. We observe qualitatively similar, but larger, anisotropies in d+Au collisions at RHIC compared to those seen in p+Pb collisions at the LHC. The larger extracted v2 values in d+Au are consistent with expectations from hydrodynamic calculations owing to the larger expected initial-state eccentricity compared with that from p+Pb collisions. When both are divided by an estimate of the initial-state eccentricity the scaled anisotropies follow a common trend with multiplicity that may extend to heavy ion data at RHIC and the LHC, where the anisotropies are widely thought to arise from hydrodynamic flow.
Collapse
|
105
|
Adare A, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Angerami A, Aoki K, Apadula N, Aramaki Y, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Bhom JH, Blau DS, Bok JS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Campbell S, Caringi A, Chen CH, Chi CY, Chiu M, Choi IJ, Choi JB, Choudhury RK, Christiansen P, Chujo T, Chung P, Chvala O, Cianciolo V, Citron Z, Cole BA, Conesa del Valle Z, Connors M, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Dayananda MK, Denisov A, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Dutta D, D'Orazio L, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grim G, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ikeda Y, Imai K, Inaba M, Isenhower D, Ishihara M, Issah M, Ivanischev D, Iwanaga Y, Jacak BV, Jia J, Jiang X, Jin J, Johnson BM, Jones T, Joo KS, Jouan D, Jumper DS, Kajihara F, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim A, Kim BI, Kim DJ, Kim EJ, Kim YJ, Kinney E, Kiss Á, Kistenev E, Kleinjan D, Kochenda L, Komkov B, Konno M, Koster J, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee KB, Lee KS, Leitch MJ, Leite MAL, Li X, Lichtenwalner P, Liebing P, Linden Levy LA, Liška T, Liu H, Liu MX, Love B, Lynch D, Maguire CF, Makdisi YI, Malik MD, Manko VI, Mannel E, Mao Y, Masui H, Matathias F, McCumber M, McGaughey PL, McGlinchey D, Means N, Meredith B, Miake Y, Mibe T, Mignerey AC, Miki K, Milov A, Mitchell JT, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Murakami T, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nam S, Newby J, Nguyen M, Nihashi M, Nouicer R, Nyanin AS, Oakley C, O'Brien E, Oda SX, Ogilvie CA, Oka M, Okada K, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park IH, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Perepelitsa D, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Qu H, Rak J, Ravinovich I, Read KF, Rembeczki S, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Ružička P, Sahlmueller B, Saito N, Sakaguchi T, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Themann H, Thomas D, Thomas TL, Togawa M, Toia A, Tomášek L, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Woody CL, Wright RM, Wysocki M, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zhou S. Nuclear modification of ψ', χc, and J/ψ production in d+Au collisions at sqrt[s(NN)]=200 GeV. PHYSICAL REVIEW LETTERS 2013; 111:202301. [PMID: 24289677 DOI: 10.1103/physrevlett.111.202301] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2013] [Revised: 08/29/2013] [Indexed: 06/02/2023]
Abstract
We present results for three charmonia states (ψ', χc, and J/ψ) in d+Au collisions at |y|<0.35 and sqrt[s(NN)]=200 GeV. We find that the modification of the ψ' yield relative to that of the J/ψ scales approximately with charged particle multiplicity at midrapidity across p+A, d+Au, and A+A results from the Super Proton Synchrotron and the Relativistic Heavy Ion Collider. In large-impact-parameter collisions we observe a similar suppression for the ψ' and J/ψ, while in small-impact-parameter collisions the more weakly bound ψ' is more strongly suppressed. Owing to the short time spent traversing the Au nucleus, the larger ψ' suppression in central events is not explained by an increase of the nuclear absorption owing to meson formation time effects.
Collapse
|
106
|
Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I, Park JH, Choi YJ, Jo J, Ryu JS, Ryu MH. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer 2013; 109:2309-15. [PMID: 24084771 PMCID: PMC3817332 DOI: 10.1038/bjc.2013.594] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Revised: 08/27/2013] [Accepted: 09/09/2013] [Indexed: 12/24/2022] Open
Abstract
Background: This prospective, phase II trial evaluated the efficacy and safety of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours (GISTs) after failure of at least imatinib and sunitinib. Methods: Patients received oral dovitinib, 500 mg once daily, for 5 consecutive days, followed by a 2-day rest, every 28 days. The primary endpoint was disease control rate (DCR; objective response+stable disease (SD)) at 24 weeks, assessed by computed tomography (CT) scan according to RECIST v1.0. Metabolic response was evaluated by positron emission tomography (PET)–CT scans performed at baseline and after 4 weeks of treatment. Results: Between September 2011 and April 2012, 30 patients were enroled. DCR at 24 weeks by RECIST v1.0 was 13% and one patient (3%) had a partial response. Based on the European Organization for Research and Treatment of Cancer PET response criteria, four patients (13%) had a metabolic partial response after 4 weeks of treatment. At a median follow-up of 8.3 months (range, 6.3–12.2 months), median progression-free survival (PFS) was 3.6 months (95% confidence interval (CI), 3.5–3.7 months) and median overall survival was 9.7 months (95% CI, 6.0–13.4 months). Metabolic progressive disease at Week 4 was significantly associated with shorter PFS (P=0.03). Grade 3/4 adverse events included asthenia (20%), neutropenia (13%), thrombocytopenia (10%), and hypertriglyceridaemia (10%). Most toxicities were manageable by dose modification. Conclusion: Dovitinib showed modest antitumour activity with manageable toxicities in heavily pretreated patients with advanced GISTs.
Collapse
|
107
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Akimoto R, Al-Bataineh H, Al-Ta'ani H, Alexander J, Angerami A, Aoki K, Apadula N, Aphecetche L, Aramaki Y, Armendariz R, Aronson SH, Asai J, Asano H, Aschenauer EC, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Bannier B, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Baumgart S, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Bing X, Blau DS, Boissevain JG, Bok JS, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Castera P, Chang BS, Chang WC, Charvet JL, Chen CH, Chernichenko S, Chi CY, Chiba J, Chiu M, Choi IJ, Choi JB, Choi S, Choudhury RK, Christiansen P, Chujo T, Chung P, Churyn A, Chvala O, Cianciolo V, Citron Z, Cleven CR, Cole BA, Comets MP, Connors M, Constantin P, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, Daugherity MS, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Ding L, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durham JM, Durum A, Dutta D, Dzhordzhadze V, D'Orazio L, Edwards S, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Gadrat S, Gainey K, Gal C, Garishvili A, Garishvili I, Glenn A, Gong H, Gong X, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guo L, Gustafsson HÅ, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Harada H, Hartouni EP, Haruna K, Hashimoto K, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Hollis RS, Holzmann W, Homma K, Hong B, Horaguchi T, Hori Y, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Inoue Y, Iordanova A, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Javani M, Jia J, Jiang X, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kaneti S, Kang BH, Kang JH, Kang JS, Kanou H, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim BI, Kim C, Kim DH, Kim DJ, Kim E, Kim EJ, Kim HJ, Kim KB, Kim SH, Kim YJ, Kim YK, Kinney E, Kiriluk K, Kiss Á, Kistenev E, Kiyomichi A, Klatsky J, Klay J, Klein-Boesing C, Kleinjan D, Kline P, Kochenda L, Kochetkov V, Komatsu Y, Komkov B, Konno M, Koster J, Kotchetkov D, Kotov D, Kozlov A, Král A, Kravitz A, Krizek F, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee B, Lee DM, Lee J, Lee K, Lee KB, Lee KS, Lee MK, Lee SH, Lee SR, Lee T, Leitch MJ, Leite MAL, Leitgab M, Leitner E, Lenzi B, Lewis B, Li X, Liebing P, Lim SH, Linden Levy LA, Liška T, Litvinenko A, Liu H, Liu MX, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Makek M, Malakhov A, Malik MD, Manion A, Manko VI, Mannel E, Mao Y, Mašek L, Masui H, Masumoto S, Matathias F, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Means N, Mendoza M, Meredith B, Miake Y, Mibe T, Mignerey AC, Mikeš P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra DK, Mishra M, Mitchell JT, Mitrovski M, Miyachi Y, Miyasaka S, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Motschwiller S, Moukhanova TV, Mukhopadhyay D, Murakami T, Murata J, Nagae T, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nattrass C, Nederlof A, Newby J, Nguyen M, Nihashi M, Niida T, Norman BE, Nouicer R, Novitzky N, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Oka M, Okada K, Omiwade OO, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park BH, Park IH, Park J, Park SK, Park WJ, Pate SF, Patel L, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Reynolds R, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Romana A, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ružička P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Sakata H, Samsonov V, Sano M, Sano S, Sarsour M, Sato S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Sen A, Seto R, Sharma D, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Skutnik S, Slunečka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Soumya M, Sourikova IV, Sparks NA, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sun J, Sziklai J, Tabaru T, Takagi S, Takagui EM, Takahara A, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Tennant E, Themann H, Thomas TL, Todoroki T, Togawa M, Toia A, Tojo J, Tomášek L, Tomášek M, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tsuji T, Vale C, Valle H, van Hecke HW, Vargyas M, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Watanabe YS, Wei F, Wei R, Wessels J, White SN, Winter D, Wolin S, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Yasin Z, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zelenski A, Zhang C, Zhou S, Zimányi J, Zolin L. Medium modification of jet fragmentation in Au+Au collisions at √[s(NN)]=200 GeV measured in direct photon-hadron correlations. PHYSICAL REVIEW LETTERS 2013; 111:032301. [PMID: 23909311 DOI: 10.1103/physrevlett.111.032301] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Indexed: 06/02/2023]
Abstract
The jet fragmentation function is measured with direct photon-hadron correlations in p+p and Au+Au collisions at √[s(NN)]=200 GeV. The p(T) of the photon is an excellent approximation to the initial p(T) of the jet and the ratio z(T)=p(T)(h)/p(T)(γ) is used as a proxy for the jet fragmentation function. A statistical subtraction is used to extract the direct photon-hadron yields in Au+Au collisions while a photon isolation cut is applied in p+p. I(AA), the ratio of hadron yield opposite the photon in Au+Au to that in p+p, indicates modification of the jet fragmentation function. Suppression, most likely due to energy loss in the medium, is seen at high z(T). The associated hadron yield at low z(T) is enhanced at large angles. Such a trend is expected from redistribution of the lost energy into increased production of low-momentum particles.
Collapse
|
108
|
Khrenov B, Panasyuk M, Garipov G, Kalmykov N, Klimov P, Morozenko V, Sharakin S, Shirokov A, Yashin I, Biktemerova S, Grinyuk A, Naumov D, Tkachev L, Tkachenko A, Saprykin O, Botvinko A, Park I, Lee J, Na G, Martinez O, Salazar H, Ponce E. Pioneering space based detector for study of cosmic rays beyond GZK Limit. EPJ WEB OF CONFERENCES 2013. [DOI: 10.1051/epjconf/20135309006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
109
|
Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Invest New Drugs 2013; 31:1300-6. [PMID: 23677653 DOI: 10.1007/s10637-013-9973-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Accepted: 05/07/2013] [Indexed: 11/26/2022]
Abstract
BACKGROUNDS A pegylated form of recombinant granulocyte-colony stimulating factor (G-CSF) was developed for prophylactic use in breast cancer. The aim of this study was to evaluate the efficacy and safety of once-per-cycle DA-3031 in patients receiving chemotherapy for breast cancer. METHODS A total of 61 patients receiving docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy were randomized in cycle 1 to receive daily injections of filgrastim (100 μg/m(2)) or a single subcutaneous injection of pegylated filgrastim DA-3031 at a dose of either 3.6 mg or 6 mg. RESULTS The mean duration of grade 4 neutropenia in cycle 1 was comparable among the treatment groups (2.48, 2.20, and 2.05 days for filgrastim, DA-3031 3.6 mg and 6 mg, respectively; P=0.275). No statistically significant differences were observed in the incidence of febrile neutropenia between the treatment groups (9.5 %, 15.0 %, and 5.0 % for filgrastim, DA-3031 3.6 mg and 6 mg, respectively; P=0.681) in cycle 1. The incidences of adverse events attributable to G-CSF were similar among the treatment groups. CONCLUSIONS Fixed doses of 3.6 mg or 6 mg DA-3031 have an efficacy comparable to that of daily injections of filgrastim in ameliorating grade 4 neutropenia in patients receiving TAC chemotherapy.
Collapse
|
110
|
Kang YK, Chang HM, Yook JH, Ryu MH, Park I, Min YJ, Zang DY, Kim GY, Yang DH, Jang SJ, Park YS, Lee JL, Kim TW, Oh ST, Park BK, Jung HY, Kim BS. Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). Br J Cancer 2013; 108:1245-51. [PMID: 23449357 PMCID: PMC3619263 DOI: 10.1038/bjc.2013.86] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND This phase 3 study evaluated the efficacy of new adjuvant chemotherapy (MFP), which intensified the mitomycin-C (MMC) plus short-term doxifluridine (Mf) for gastric cancer. PATIENTS AND METHODS A total of 855 patients (424 in Mf, 431 in MFP) with pathological stage II-IV (M0) gastric cancer after D2 gastrectomy were randomly assigned to receive either Mf (MMC 20 mg m(-2), followed by oral doxifluridine 460-600 mg m(-2) per day for 3 months) or MFP (MMC 20 mg m(-2), followed by oral doxifluridine 460-600 mg m(-2) per day for 12 months with 6 monthly infusions of 60 mg m(-2) of cisplatin) chemotherapy. RESULTS With a median follow-up of 6.6 years, there was no difference between the two groups in recurrence-free survival (RFS) (5-year RFS 61.1% in Mf and 57.9% in MFP; hazard ratio 1.10 (95% CI 0.89-1.35); P=0.39) and overall survival (OS) (5-year OS 66.5% in Mf and 65.0% in MFP; hazard ratio 1.11 (95% CI 0.89-1.39); P=0.33). CONCLUSION Intensification of Mf adjuvant chemotherapy by prolonging the duration of oral fluoropyrimidine and adding cisplatin was safe but not effective to improve the survivals in curatively resected gastric cancer patients.
Collapse
|
111
|
Jeong S, Nam JW, Ahn KB, Park IH, Kim SW, Lee J, Lim H, Brandt S, Budtz-Jørgensen C, Castro-Tirado AJ, Chen P, Cho MH, Choi JN, Grossan B, Huang MA, Jung A, Kim JE, Kim MB, Kim YW, Linder EV, Min KW, Na GW, Panasyuk MI, Ripa J, Reglero V, Smoot GF, Suh JE, Svertilov S, Vedenkin N, Yashin I. Slewing Mirror Telescope optics for the early observation of UV/optical photons from Gamma-Ray Bursts. OPTICS EXPRESS 2013; 21:2263-2278. [PMID: 23389206 DOI: 10.1364/oe.21.002263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
We report on design, manufacture, and testing of a Slewing Mirror Telescope (SMT), the first of its kind and a part of Ultra-Fast Flash Observatory-pathfinder (UFFO-p) for space-based prompt measurement of early UV/optical light curves from Gamma-Ray Bursts (GRBs). Using a fast slewing mirror of 150 mm diameter mounted on a 2 axis gimbal stage, SMT can deliver the images of GRB optical counterparts to the intensified CCD detector within 1.5~1.8 s over ± 35 degrees in the slewing field of view. Its Ritchey-Chrétien telescope of 100 mm diameter provides a 17 × 17 arcmin² instantaneous field of view. Technical details of design, construction, the laboratory performance tests in space environments for this unique SMT are described in conjunction with the plan for in-orbit operation onboard the Lomonosov satellite in 2013.
Collapse
|
112
|
Kim SH, Choi YS, Lee JG, Park IH, Oh YJ. Effects of a 1:1 inspiratory to expiratory ratio on respiratory mechanics and oxygenation during one-lung ventilation in the lateral decubitus position. Anaesth Intensive Care 2012. [PMID: 23194211 DOI: 10.1177/0310057x1204000613] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Prolonged inspiratory to expiratory (I:E) ratio ventilation may have both positive and negative effects on respiratory mechanics and oxygenation during one-lung ventilation (OLV), but definitive information is currently lacking. We therefore compared the effects of volume-controlled ventilation with I:E ratios of 1:1 and 1:2 on respiratory mechanics and oxygenation during OLV. Fifty-six patients undergoing thoracoscopic lobectomy were randomly assigned volume-controlled ventilation with an I:E ratio of 1:1 (group 1:1, n=28) or 1:2 (group 1:2, n=28) during OLV. Arterial and central venous blood gas analyses and respiratory variables were recorded 15 minutes into two-lung ventilation, at 30 and 60 minutes during OLV, and 15 minutes after two-lung ventilation was re-initiated. Peak and plateau airway pressures in cmH2O [standard deviation] during OLV were significantly lower in group 1:1 than in group 1:2 (P <0.01) (19 [3] and 23 [4]; 16 [3] and 19 [5], respectively). The arterial to end-tidal carbon dioxide tension difference was significantly lower in group 1:1 than in group 1:2 (P <0.01), (0.5 [0.3] and 1.1 [0.5]). There were no significant differences in PaO2 during OLV between the two groups (OLV30, P=0.856; OLV60, P=0.473). In summary, volume-controlled ventilation with an I:E ratio of 1:1 reduced peak and plateau airway pressures improved dynamic compliance and efficiency of alveolar ventilation, but it did not improve arterial oxygenation in a substantial manner. Furthermore, the associated increase in mean airway pressure might have reduced cardiac output, resulting in a lower central venous oxygen saturation.
Collapse
|
113
|
Adare A, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Angerami A, Aoki K, Apadula N, Aramaki Y, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bhom JH, Blau DS, Bok JS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Campbell S, Caringi A, Chen CH, Chi CY, Chiu M, Choi IJ, Choi JB, Choudhury RK, Christiansen P, Chujo T, Chung P, Chvala O, Cianciolo V, Citron Z, Cole BA, Conesa Del Valle Z, Connors M, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Dayananda MK, Denisov A, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Dutta D, D'Orazio L, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grim G, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ikeda Y, Imai K, Inaba M, Isenhower D, Ishihara M, Issah M, Ivanischev D, Iwanaga Y, Jacak BV, Jia J, Jiang X, Jin J, Johnson BM, Jones T, Joo KS, Jouan D, Jumper DS, Kajihara F, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim A, Kim BI, Kim DJ, Kim EJ, Kim YJ, Kinney E, Kiss A, Kistenev E, Kleinjan D, Kochenda L, Komkov B, Konno M, Koster J, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee KB, Lee KS, Leitch MJ, Leite MAL, Li X, Lichtenwalner P, Liebing P, Linden Levy LA, Liška T, Liu H, Liu MX, Love B, Lynch D, Maguire CF, Makdisi YI, Malik MD, Manko VI, Mannel E, Mao Y, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mibe T, Mignerey AC, Miki K, Milov A, Mitchell JT, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Murakami T, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nam S, Newby J, Nguyen M, Nihashi M, Nouicer R, Nyanin AS, Oakley C, O'Brien E, Oda SX, Ogilvie CA, Oka M, Okada K, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park IH, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Qu H, Rak J, Ravinovich I, Read KF, Rembeczki S, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Ružička P, Sahlmueller B, Saito N, Sakaguchi T, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Themann H, Thomas D, Thomas TL, Togawa M, Toia A, Tomášek L, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Woody CL, Wright RM, Wysocki M, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zhou S. Cold-nuclear-matter effects on heavy-quark production in d+Au collisions at sqrt[S(NN)]=200 GeV. PHYSICAL REVIEW LETTERS 2012; 109:242301. [PMID: 23368311 DOI: 10.1103/physrevlett.109.242301] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Indexed: 06/01/2023]
Abstract
The PHENIX experiment has measured electrons and positrons at midrapidity from the decays of hadrons containing charm and bottom quarks produced in d+Au and p+p collisions at sqrt[S(NN)]=200 GeV in the transverse-momentum range 0.85 ≤ p(T)(e) ≤ 8.5 GeV/c. In central d+Au collisions, the nuclear modification factor R(dA) at 1.5<p(T)<5 GeV/c displays evidence of enhancement of these electrons, relative to those produced in p+p collisions, and shows that the mass-dependent Cronin enhancement observed at the Relativistic Heavy Ion Collider extends to the heavy D meson family. A comparison with the neutral-pion data suggests that the difference in cold-nuclear-matter effects on light- and heavy-flavor mesons could contribute to the observed differences between the π(0) and heavy-flavor-electron nuclear modification factors R(AA).
Collapse
|
114
|
Park KH, Lim C, Kim TH, Park I, Jung Y. Outcome of extensive descending aorta repair adopting present concepts of spinal cord preservatio. THE JOURNAL OF CARDIOVASCULAR SURGERY 2012:R37126807. [PMID: 23138604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIM: Preoperative radiological identification of the Adamkiewicz artery and intraoperative neurologic monitoring are known to be helpful for preventing paraplegia after thoracoabdominal aorta replacement. To answer whether they should be used routinely, we investigated the incidence of spinal cord ischemia after extensive descending aortic repair without using such modalities. METHODS: We retrospectively reviewed the outcome of 95 patients who underwent extensive descending thoracic (DTA) or thoracoabdominal aorta (TAA) repair without the Adamkiewicz artery identification or neurologic monitoring from 2006 through 2010. Spinal cord protection strategy consisted of distal aortic perfusion, cerebrospinal fluid drainage, mild hypothermia, and maintenance of hypertension (systolic≥120mmHg) through the second postoperative day. A few segmental arteries were empirically selected for reimplantation based on the size and the amount of backbleeding; overall 1.4 per patient, 0.3 for DTA, 1.4 for type I, 2.4 for type II, 0.9 for type III, and 0 for type IV TAA. RESULTS: Two patients died early after surgery. All the remaining patients awoke without paraplegia or paraparesis. Delayed deficit occurred in 7 patients (7.4%) after hypotensive events caused by sedation, bleeding, respiratory distress, or cardiac dysfunction. Three patients (3.2%) became permanently paraplegic and the other four recovered completely within 48 hours after cerebrospinal fluid drainage and elevation of systemic blood pressure. CONCLUSION: Even without the Adamkiewicz artery identification and neuromonitoring, the incidence of immediate paraplegia could be kept low by applying the strategy based on the modern concept of cord perfusion. The relatively high incidence of delayed deficit suggests the importance of postoperative hemodynamic management and prevention of cardiopulmonary complications.
Collapse
|
115
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Akimoto R, Al-Ta'ani H, Alexander J, Angerami A, Aoki K, Apadula N, Aramaki Y, Asano H, Aschenauer EC, Atomssa ET, Awes TC, Azmoun B, Babintsev V, Bai M, Bannier B, Barish KN, Bassalleck B, Bathe S, Baublis V, Baumgart S, Bazilevsky A, Belmont R, Berdnikov A, Berdnikov Y, Bing X, Blau DS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Butsyk S, Campbell S, Castera P, Chen CH, Chi CY, Chiu M, Choi IJ, Choi JB, Choi S, Choudhury RK, Christiansen P, Chujo T, Chvala O, Cianciolo V, Citron Z, Cole BA, Connors M, Csanád M, Csörgő T, Dairaku S, Datta A, Daugherity MS, David G, Denisov A, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Ding L, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, D'Orazio L, Edwards S, Efremenko YV, Engelmore T, Enokizono A, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Frantz JE, Franz A, Frawley AD, Fukao Y, Fusayasu T, Gainey K, Gal C, Garishvili A, Garishvili I, Glenn A, Gong X, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guo L, Gustafsson HÅ, Hachiya T, Haggerty JS, Hahn KI, Hamagaki H, Hanks J, Hashimoto K, Haslum E, Hayano R, He X, Hemmick TK, Hester T, Hill JC, Hollis RS, Homma K, Hong B, Horaguchi T, Hori Y, Huang S, Ichihara T, Iinuma H, Ikeda Y, Imrek J, Inaba M, Iordanova A, Isenhower D, Issah M, Isupov A, Ivanischev D, Jacak BV, Javani M, Jia J, Jiang X, Johnson BM, Joo KS, Jouan D, Kamin J, Kaneti S, Kang BH, Kang JH, Kang JS, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kim BI, Kim C, Kim DJ, Kim EJ, Kim HJ, Kim KB, Kim YJ, Kim YK, Kinney E, Kiss A, Kistenev E, Klatsky J, Kleinjan D, Kline P, Komatsu Y, Komkov B, Koster J, Kotchetkov D, Kotov D, Král A, Krizek F, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee B, Lee DM, Lee J, Lee KB, Lee KS, Lee SH, Lee SR, Leitch MJ, Leite MAL, Leitgab M, Lewis B, Lim SH, Linden Levy LA, Litvinenko A, Liu MX, Love B, Maguire CF, Makdisi YI, Makek M, Malakhov A, Manion A, Manko VI, Mannel E, Masumoto S, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Mendoza M, Meredith B, Miake Y, Mibe T, Mignerey AC, Milov A, Mishra DK, Mitchell JT, Miyachi Y, Miyasaka S, Mohanty AK, Moon HJ, Morrison DP, Motschwiller S, Moukhanova TV, Murakami T, Murata J, Nagae T, Nagamiya S, Nagle JL, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nattrass C, Nederlof A, Nihashi M, Nouicer R, Novitzky N, Nyanin AS, O'Brien E, Ogilvie CA, Okada K, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park BH, Park IH, Park SK, Pate SF, Patel L, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Qu H, Rak J, Ravinovich I, Read KF, Reynolds R, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rukoyatkin P, Sahlmueller B, Saito N, Sakaguchi T, Samsonov V, Sano M, Sarsour M, Sawada S, Sedgwick K, Seidl R, Sen A, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soltz RA, Sondheim WE, Sorensen SP, Soumya M, Sourikova IV, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Sukhanov A, Sun J, Sziklai J, Takagui EM, Takahara A, Taketani A, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tennant E, Themann H, Todoroki T, Tomášek L, Tomášek M, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Tsuji T, Vale C, van Hecke HW, Vargyas M, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Watanabe YS, Wei F, Wei R, White SN, Winter D, Wolin S, Woody CL, Wysocki M, Yamaguchi YL, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Younus I, Yushmanov IE, Zajc WA, Zelenski A, Zolin L. Evolution of π(0) suppression in Au+Au collisions from √(s(NN))=39 to 200 GeV. PHYSICAL REVIEW LETTERS 2012; 109:152301. [PMID: 23102299 DOI: 10.1103/physrevlett.109.152301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2012] [Indexed: 06/01/2023]
Abstract
Neutral-pion π(0) spectra were measured at midrapidity (|y|<0.35) in Au+Au collisions at √(s(NN))=39 and 62.4 GeV and compared with earlier measurements at 200 GeV in a transverse-momentum range of 1<p(T)<10 GeV/c. The high-p(T) tail is well described by a power law in all cases, and the powers decrease significantly with decreasing center-of-mass energy. The change of powers is very similar to that observed in the corresponding spectra for p+p collisions. The nuclear modification factors (R(AA)) show significant suppression, with a distinct energy, centrality, and p(T) dependence. Above p(T)=7 GeV/c, R(AA) is similar for √(s(NN))=62.4 and 200 GeV at all centralities. Perturbative-quantum-chromodynamics calculations that describe R(AA) well at 200 GeV fail to describe the 39 GeV data, raising the possibility that, for the same p(T) region, the relative importance of initial-state effects and soft processes increases at lower energies. The p(T) range where π(0) spectra in central Au+Au collisions have the same power as in p+p collisions is ≈5 and 7 GeV/c for √(s(NN))=200 and 62.4 GeV, respectively. For the √(s(NN))=39 GeV data, it is not clear whether such a region is reached, and the x(T) dependence of the x(T)-scaling power-law exponent is very different from that observed in the √(s(NN))=62 and 200 GeV data, providing further evidence that initial-state effects and soft processes mask the in-medium suppression of hard-scattered partons to higher p(T) as the collision energy decreases.
Collapse
|
116
|
Lee JL, Park K, Park I, Park S, Ahn Y, Ahn JH, Song C, Hong J, Kim CS, Ahn H. Mammalian Target of Rapamycin Inhibitors Versus Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF TKI) as Second-Line Therapy in Patients with Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF TKI: Single Center Retrospective Analysis. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32419-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
117
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aramaki Y, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Bok JS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chen CH, Chi CY, Chiu M, Choi IJ, Choudhury RK, Christiansen P, Chujo T, Chung P, Chvala O, Cianciolo V, Citron Z, Cole BA, Connors M, Constantin P, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Denisov A, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Dutta D, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Hartouni EP, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Ikeda Y, Imai K, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kim BI, Kim DH, Kim DJ, Kim E, Kim EJ, Kim SH, Kim YJ, Kinney E, Kiriluk K, Kiss A, Kistenev E, Klein-Boesing C, Kochenda L, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee K, Lee KB, Lee KS, Leitch MJ, Leite MAL, Leitner E, Lenzi B, Li X, Liebing P, Linden Levy LA, Liška T, Litvinenko A, Liu H, Liu MX, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mignerey AC, Mikeš P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Oka M, Okada K, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park IH, Park J, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ružička P, Sahlmueller B, Saito N, Sakaguchi T, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Sparks NA, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tomášek L, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zhang C, Zhou S, Zolin L. Observation of direct-photon collective flow in Au + Au collisions at √s(NN)] = 200 GeV. PHYSICAL REVIEW LETTERS 2012; 109:122302. [PMID: 23005942 DOI: 10.1103/physrevlett.109.122302] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/21/2011] [Indexed: 06/01/2023]
Abstract
The second Fourier component v(2) of the azimuthal anisotropy with respect to the reaction plane is measured for direct photons at midrapidity and transverse momentum (p(T)) of 1-12 GeV/c in Au + Au collisions at √s(NN)] = 200 GeV. Previous measurements of this quantity for hadrons with p(T) < 6 GeV/c indicate that the medium behaves like a nearly perfect fluid, while for p(T) > 6 GeV/c a reduced anisotropy is interpreted in terms of a path-length dependence for parton energy loss. In this measurement with the PHENIX detector at the Relativistic Heavy Ion Collider we find that for p(T) > 4 GeV/c the anisotropy for direct photons is consistent with zero, which is as expected if the dominant source of direct photons is initial hard scattering. However, in the p(T) < 4 GeV/c region dominated by thermal photons, we find a substantial direct-photon v(2) comparable to that of hadrons, whereas model calculations for thermal photons in this kinematic region underpredict the observed v(2).
Collapse
|
118
|
Park S, Lee J, Park I, Park K, Ahn J, Lee D, Song C, Hong J, Kim C, Ahn H. Comparative Efficacy of Sunitinib Versus Sorafenib as the First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33445-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
119
|
Park IH, Han HS, Lee H, Lee KS, Kang HS, Lee S, Kim SW, Jung S, Ro J. Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer. Ann Oncol 2012; 23:2283-2289. [PMID: 22377562 DOI: 10.1093/annonc/mds006] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We investigated the relationship between resumption or persistence of menstruation after cytotoxic chemotherapy (RM) and disease-free survival (DFS) in premenopausal patients with early breast cancer. METHODS Medical records from 872 patients who received cytotoxic chemotherapy for stage I to III breast cancer were retrospectively reviewed. RESULTS The median patient age was 41 years (range, 21-54) and the median follow-up duration was 6.2 years (range, 0.7-10.4). Six hundred ninety-two patients (79.4%) were hormone receptor (HR) positive and the majority of these received tamoxifen therapy after completing chemotherapy. The chemotherapy-induced amenorrhea (CIA) rate was 76.7% (n = 669), and 51.8% (n = 452) experienced RM during the follow-up period. One hundred twenty-one (13.9%) patients had persistent menstruation without CIA. DFS was significantly affected by younger age at diagnosis (≤35 years) (P = 0.013), tumor size > 2 cm (P < 0.001), node positivity (P < 0.001), HR negativity (P < 0.001), HER2 positivity (P = 0.010), and RM (P < 0.001). HR negativity [hazard ratio 1.7, 95% confidence interval (CI) 1.2-2.4, P = 0.006], tumor size > 2 cm (hazard ratio 2.1, 95% CI 1.4-3.0, P < 0.001), node positivity (hazard ratio 3.0, 95% CI 2.0-4.7, P < 0.001), and RM (hazard ratio 1.8, 95% CI 1.2-2.7, P = 0.004) remained significant factors for DFS on multivariate analysis. CONCLUSIONS A considerable proportion of premenopausal patients treated with chemotherapy experienced RM after CIA. RM was a poor prognostic factor for DFS in premenopausal patients with early breast cancer.
Collapse
|
120
|
Park I, Park K, Park S, Ahn Y, Ahn J, Choi H, Song C, Ahn H, Hong J, Lee J. Recist Response of the Primary Lesion in Metastatic Renal Cell Carcinomas Treated with Sunitinib: Does the Primary Lesion have to be regarded as a Target Lesion? Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33405-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
121
|
Park J, Ryu M, Kim H, Ryoo B, Park I, Park Y, Oh S, Yook J, Kim B, Kang Y. Identification of Risk Factors of Relapse after Curative Surgical Resection in Stage I Gastric Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33254-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
122
|
Kang Y, Ryu M, Lee J, Park I, Park J, Ryoo B. A Phase II Study of Dovitinib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure of Two or More Tyrosine Kinase Inhibitors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34064-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
123
|
Yoo C, Ryu M, Ryoo B, Koo D, Park I, Kang Y. A Phase I Dose-Finding Study of Vorinostat (V) Combined with Capecitabine (X) and Cisplatin (P) as First-Line Therapy in Patients with advanced Gastric Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33277-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
124
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aramaki Y, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Bok JS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chen CH, Chi CY, Chiu M, Choi IJ, Choudhury RK, Christiansen P, Chujo T, Chung P, Chvala O, Cianciolo V, Citron Z, Cole BA, Connors M, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Denisov A, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Dutta D, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Hartouni EP, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Ikeda Y, Imai K, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kim BI, Kim DH, Kim DJ, Kim E, Kim EJ, Kim SH, Kim YJ, Kinney E, Kiriluk K, Kiss Á, Kistenev E, Kochenda L, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee K, Lee KB, Lee KS, Leitch MJ, Leite MAL, Leitner E, Lenzi B, Li X, Liebing P, Linden Levy LA, Liška T, Litvinenko A, Liu H, Liu MX, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mignerey AC, Mikeš P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Oka M, Okada K, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park IH, Park J, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ružička P, Sahlmueller B, Saito N, Sakaguchi T, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Sparks NA, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tomášek L, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zhang C, Zhou S, Zolin L. Measurements of higher order flow harmonics in Au+Au collisions at √s(NN)=200 GeV. PHYSICAL REVIEW LETTERS 2011; 107:252301. [PMID: 22243067 DOI: 10.1103/physrevlett.107.252301] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/22/2011] [Revised: 09/27/2011] [Indexed: 05/31/2023]
Abstract
Flow coefficients ν(n) for n=2, 3, 4, characterizing the anisotropic collective flow in Au+Au collisions at √s(NN)=200 GeV, are measured relative to event planes Ψ(n), determined at large rapidity. We report ν(n) as a function of transverse momentum and collision centrality, and study the correlations among the event planes of different order n. The ν(n) are well described by hydrodynamic models which employ a Glauber Monte Carlo initial state geometry with fluctuations, providing additional constraining power on the interplay between initial conditions and the effects of viscosity as the system evolves. This new constraint can serve to improve the precision of the extracted shear viscosity to entropy density ratio η/s.
Collapse
|
125
|
Park IH, Lee KS, Shin KH, Ro J. P4-17-12: Analysis of Predictive and Prognostic Factors for Metastatic Breast Cancer Patients with Brain Metastasis Treated by Whole Brain Radiotherapy. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-17-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background We addressed the progression free survival of brain metastasis (PFS_BM) in metastatic breast cancer (MBC) patients treated by whole brain radiotherapy (WBRT) for brain metastasis (BM). In addition, we investigated predictive and prognostic factors for the PFS_BM and OS_BM.
Patients and methods A total of 212 patients with BM, treated by WBRT at the National Cancer Center between January 2000 and December 2010 were reviewed. The PFS_BM was defined as the time interval from the date of start of WBRT to the date of a progression of metastatic lesions in the brain or death or last follow-up.
Results The median age of patients was 45 years (range, 22–72 years) and the median time to brain metastasis was 12.7 months (range, 0.0−72.8 months).
Of all patients, 50 (23.6%) patients were hormone receptor (HR) positive and 104 (49.1%) HER2 positive. Six patients received a surgery or a focal radiotherapy for metastatic lesions prior to WBRT. Seventy one (33.4%) patients had well controlled extracranial systemic disease (CR+PR+SD) when brain metastasis was diagnosed. The median survival after BM (OS_BM) was 5.4 months (95% CI, 4.4−6.4 months) and approximately 14.6% of patients died mainly of progressive brain metastasis. The PFS_BM was significantly affected by poor performance status (PS ≥3) (P<0.001), uncontrolled systemic disease status (P=0.029), disease free interval (DFI) < 2 years (P=0.011), no chemotherapy after BM (P<0.001), and HER2 positivity (P=0.002). Of those, poor PS, no chemotherapy after BM, and uncontrolled systemic disease status were remained important factors on a multivariate analysis. In terms of OS_BM, poor PS (P<0.001), older age (P=0.005), number of systemic metastatic sites >3 (P<0.001), uncontrolled systemic disease status (P<0.001), disease free interval (DFI) < 2 years (P=0.014), no chemotherapy after BM (P<0.001), and visceral involvement (P=0.009) were significant factors. Of those, poor PS (P<0.001), uncontrolled systemic disease status (P<0.001), and no chemotherapy after BM (P<0.001) were important factors for shorter OS_BM when adjusted with other factors.
Conclusions Uncontrolled extracranial systemic disease status, no chemotherapy after BM, and poor PS were significant factors for shorter PFS_BM and overall survival after brain metastasis.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-17-12.
Collapse
|